Abstract：
The treatment of non-infectious uveitis affecting the posterior segment of the eye has been revolutionized by the development of sustained-release corticosteroid implants over the past decade. Their use is now supported by healthcare systems that have licensed and commissioned them on the basis of the high-quality randomised controlled trials that formed part of their development and which have informed clinicians as to their benefits and risks. In particular, they have provided an alternative mode of treatment for patients who do not wish to be systemically immunosuppressed, or in whom such immunosuppression is less desirable, such as those with unilateral disease or those with concurrent illnesses such as diabetes mellitus, renal disease or osteoporosis that are negatively impacted by systemic corticosteroids or other immunosuppressive agents. In this article, we review the evidence for the use of the major licensed corticosteroid implants and assess the advantages and disadvantages of each.
摘要：
在过去的十年中，持续释放的皮质类固醇植入物的开发彻底改变了影响眼后段的非感染性葡萄膜炎的治疗。它们的使用现在得到了医疗保健系统的支持，这些系统已经根据高质量的随机对照试验获得了许可和委托，这些试验是其开发的一部分，并已告知临床医生其益处和风险。特别是,他们为不希望全身免疫抑制的患者提供了一种替代治疗模式，或者这种免疫抑制不太可取的人，例如患有单侧疾病或患有糖尿病等并发疾病的患者，受到全身性皮质类固醇或其他免疫抑制剂负面影响的肾脏疾病或骨质疏松症。在这篇文章中,我们回顾了使用主要许可的皮质类固醇植入物的证据,并评估了每种植入物的优缺点.
